News

Mycenax Reports 2022 H1 EPS of NT$0.32 with business expansion from traditional biologics to allogeneic cell therapy and emerging biologics.

Mycenax and Cytiva Enable First Continuous Manufacturing Process Development Satellite Laboratory in Taiwan

Mycenax signs an MOU with CHO PHARMA, cooperating to expand the production and application of next-generation antibodies

Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System

Mycenax Announces the Sale of LusiNEX to Gedeon Richter

Mycenax signs agreement with Hummingbird Bioscience for production of anti-vista antibody HMBD-002 for cancer clinical trial.

Mycenax won the First Prize of Merck’s Advance Biotech Grant Program

Mycenax cooperates with Norwegian Vectron Biosolutions AS to create a high-volume microbiology platform for global CDMO

Mycenax Biotech Inc. has been shortlisted as a finalist in the CPhI Pharma Awards!

Mycenax Biotech Inc. announces TGA approval of phase I clinical trial authorization application for LusiNEX to treat aut